Wednesday, September 04, 2019 2:13:06 PM
"I thought I would point out some key differences and advantages to the design of our TRILOGY studies as compared to our Phase 2 program. As I mentioned, we expect a total of approximately 500 patients to complete the two TRILOGY studies. And there are significant differences in the clinical profile of these patients compared to those who completed our Phase 2 studies."
https://seekingalpha.com/article/4272297-acasti-pharma-inc-acst-ceo-jan-dalvise-q4-2019-results-earnings-call-transcript
"China is actually the third largest pharmaceutical market in the world with an average compounded annual sales growth rate of approximately 20% over the last 10 years. In addition let me remind you that China represents an important market for Acasti given the high prevalence of hypertriglyceridemia and the need for an effective safe and efficiently absorbed drug for the treatment of cardiometabolic related diseases"
In the new report, Earl S. Ford, MD, of the CDC, and his colleagues looked at a nationally representative group of 5,610 people 20 and older. They found that 33.1% had triglyceride levels above 150 mg/dL, while 17.9% had levels above 200 mg/dL, 1.7% had levels of 500 mg/dL or above, and 0.4% had levels higher than 1,000 mg/dL
https://www.health.com/cholesterol/americans-high-triglycerides
Approximately one-third of the US population has elevations in circulating triglyceride levels [1, 2]. Most of these elevations are mild to moderate in nature, and the pathophysiology involves hepatic overproduction of very low?density lipoproteins (VLDLs), the principal triglyceride-carrying lipoprotein circulating in the fasting state [3, 4]. A subset of patients have “very severe hypertriglyceridemia,” defined by the Endocrine Society as serum triglyceride concentration ≥2000 mg/dL (22.6 mmol/L) [5]. In addition to VLDL overproduction, the pathophysiology of very severe hypertriglyceridemia involves defective triglyceride clearance due to either saturation or dysfunction of the enzyme lipoprotein lipase (LPL), resulting in accumulation of chylomicrons and VLDLs [3, 6, 7].
https://consumer.healthday.com/circulatory-system-information-7/blood-disorder-news-68/americans-blood-triglyceride-levels-dropping-cdc-699187.html
Recent ACST News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/06/2024 08:07:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 12:00:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 11:30:40 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/07/2024 08:14:52 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/05/2024 04:15:03 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/31/2024 11:22:52 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/11/2024 01:10:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:18:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 01:00:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 12:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 12:30:09 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM